LY293111 (Synonyms: Etalocib; VML 295) |
Catalog No.GC44096 |
LY293111 (LY293111), un antagoniste des récepteurs des leucotriènes B4 actif par voie orale, inhibe la liaison de [3H]LTB4, avec un Ki de 25 nM.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 161172-51-6
Sample solution is provided at 25 µL, 10mM.
Leukotriene B4 (LTB4) is a dihydroxy fatty acid derived from the 5-lipoxygenase pathway of arachidonic acid metabolism and is an important mediator of the inflammatory process. LY293111 is a potent antagonist of the leukotriene B4 (LTB4) receptor, BLT1, that inhibits the specific binding of radiolabeled-LTB4 to isolated human neutrophils with an IC50 value of 17.6 nM and inhibits the LTB4-induced chemotaxis of human neutrophils with an IC50 value of 6.3 nM. LY293111 inhibits growth of MiaPaCa-2 and AsPC-1 human pancreatic cancer cells in vitro (250-1,000 nM) and subcutaneous xenografts in athymic mice (250 mg/kg/day), inducing apoptosis and S-phase arrest.
Average Rating: 5
(Based on Reviews and 31 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *